humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumab
Phase 1/2UNKNOWN 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
Conditions
Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
Trial Timeline
Jan 1, 2010 → Aug 1, 2014
NCT ID
NCT01279707About humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumab
humanised monoclonal antibody, veltuzumab + humanised monoclonal antibody epratuzumab + humanised monoclonal antibodies veltuzumab and epratuzumab is a phase 1/2 stage product being developed by Gilead Sciences for Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT01279707. Target conditions include Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01279707 | Phase 1/2 | UNKNOWN |
Competing Products
20 competing products in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia